Nuvation Bio (NYSE:NUVB) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 5.88 percent decrease over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $31.687 million which beat the analyst consensus estimate of $27.505 million by 15.20 percent. This is a 555.64 percent increase over sales of $4.833 million the same period last year.